QNTM · Company research
Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built - MarketBeat | Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| Quantum BioPharma Ltd. (QNTM) Stock Price, News, Quote & History - Yahoo! Finance Canada | Quantum BioPharma Ltd. (QNTM) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Grant & Eisenhofer Appointed Lead Counsel in Lawsuit Alleging CIBC and RBC Manipulated Quantum BioPharma Stock - TradingView | Grant & Eisenhofer Appointed Lead Counsel in Lawsuit Alleging CIBC and RBC Manipulated Quantum BioPharma Stock TradingView | View source ↗ | TradingView | Oct 8, 2026 | neutral | 0 | 0.6 |
| Unbuzzd royalties give Quantum BioPharma (QNTM) 7% of sales until payments total $250M, then 3% forever. - Stock Titan | Unbuzzd royalties give Quantum BioPharma (QNTM) 7% of sales until payments total $250M, then 3% forever. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Quantum BioPharma Taps Thermo Fisher to Launch Phase 2 Lucid-MS Trial - The Globe and Mail | Quantum BioPharma Taps Thermo Fisher to Launch Phase 2 Lucid-MS Trial The Globe and Mail | View source ↗ | The Globe and Mail | Oct 7, 2026 | neutral | 0 | 0.6 |
| Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis | Quantum BioPharma has entered into a Study Start-Up Agreement with Thermo Fisher Scientific's PPD Clinical Research Business to implement its Phase 2 clinical trial of Lucid-MS, an investigational neuroprotective therapy targeting demyelination in progressive multiple sclerosis. The agreement marks a significant milestone following FDA clearance and represents the initiation of formal study start-up activities. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 0.5 | 1 |
| Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis | Quantum BioPharma has entered into a Study Start-Up Agreement with Thermo Fisher Scientific's PPD Clinical Research Business to implement its Phase 2 clinical trial of Lucid-MS, an investigational neuroprotective therapy targeting demyelination in progressive multiple sclerosis. The agreement marks a significant milestone following FDA clearance and represents the initiation of formal study start-up activities. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 0.5 | 1 |
| Preparations begin for Quantum BioPharma's planned Phase 2 multiple sclerosis drug trial - Stock Titan | Preparations begin for Quantum BioPharma's planned Phase 2 multiple sclerosis drug trial Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| VanEck Quantum Computing UCITS ETF A USD Acc (QNTM.MI) stock price, news, quote and history - Yahoo Finance Australia | VanEck Quantum Computing UCITS ETF A USD Acc (QNTM.MI) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 6, 2026 | neutral | 0 | 0.6 |
| A passive investor reports 4.95% ownership of Quantum Biopharma (QNTM). - Stock Titan | A passive investor reports 4.95% ownership of Quantum Biopharma (QNTM). Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing - Benzinga | Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing Benzinga | View source ↗ | Benzinga | Sep 25, 2026 | neutral | 0 | 0.6 |
| An analyst sets an $8 price target for Quantum BioPharma - Stock Titan | An analyst sets an $8 price target for Quantum BioPharma Stock Titan | View source ↗ | Stock Titan | Sep 17, 2026 | neutral | 0 | 0.6 |
| Quantum BioPharma Stock Slides as Bearish Momentum, Funding Risk and Biotech Volatility Pressure CN:QNTM - kalkine.ca | Quantum BioPharma Stock Slides as Bearish Momentum, Funding Risk and Biotech Volatility Pressure CN:QNTM kalkine.ca | View source ↗ | kalkine.ca | Aug 19, 2026 | neutral | 0 | 0.6 |
| These stocks are moving in today's pre-market session - ChartMill | These stocks are moving in today's pre-market session ChartMill | View source ↗ | ChartMill | Aug 17, 2026 | neutral | 0 | 0.6 |
| Quantinuum (QNTM) Stock Wrestles With IPO Charge After Revenue Jump - Simply Wall Street | Quantinuum (QNTM) Stock Wrestles With IPO Charge After Revenue Jump Simply Wall Street | View source ↗ | Simply Wall Street | Aug 13, 2026 | neutral | 0 | 0.6 |
| Quantum BioPharma Ltd. Closes CAD$123,487.43 Debt Settlement Through Share Issuance - Quiver Quantitative | Quantum BioPharma Ltd. Closes CAD$123,487.43 Debt Settlement Through Share Issuance Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 30, 2026 | neutral | 0 | 0.6 |
| Quantum BioPharma Ltd. Announces CAD$123,487 Debt Settlement Through Share Issuance | QNTM Stock News - Quiver Quantitative | Quantum BioPharma Ltd. Announces CAD$123,487 Debt Settlement Through Share Issuance | QNTM Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 20, 2026 | neutral | 0 | 0.6 |
| Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM) - Yahoo Finance | Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM) Yahoo Finance | View source ↗ | Yahoo Finance | May 18, 2026 | neutral | 0 | 0.6 |
| Why Did QNTM Stock Pop In Pre-Market Today? - Stocktwits | Why Did QNTM Stock Pop In Pre-Market Today? Stocktwits | View source ↗ | Stocktwits | Mar 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.